News
PRVB
24.98
0.00%
0.00
Tourlite Capital Management Q4 2023 Investor Letter
Tourlite Capital Management, LP is an asset management firm focused on long/short equity investing in public companies. Tourlite Fund, LP Founder Class returned 1.1% for the Fourth Quarter of 2023 and 8.8%. The fund has returned 14.3% since inception in April 2022.
Seeking Alpha · 01/27 09:45
UPDATE 1-France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln
France's Sanofi to buy U.S. Drugs project INBRX-101 for about $2.2 bln. Sanofi agrees to buy the drug development project from its parent company Inhibrx Inc. The global pharmaceuticals sector has seen a wave of takeover deals in recent months.
Reuters · 01/23 06:29
UPDATE 1-Sanofi lifts earnings outlook on new drug launches, Dupixent sales
Reuters · 07/28/2023 06:15
Provention Bio gains after HSR waiting period for Sanofi deal expired
Seeking Alpha · 04/26/2023 13:11
Sanofi Announced Earlier: Hart-Scott-Rodino Waiting Period Expired For Sanofi's Acquisition Of Provention Bio
Benzinga · 04/26/2023 08:49
*Sanofi: All Other Terms and Conditions of Offer Remain Unchanged
Dow Jones · 04/26/2023 06:07
*Sanofi: Consummation of Offer Remains Subject to Various Conditions
Dow Jones · 04/26/2023 06:06
*Sanofi: Offer Is Scheduled to Expire Wednesday, May Be Extended
Dow Jones · 04/26/2023 06:06
*Sanofi: Expiration Means Condition to the Offer Has Been Satisfied
Dow Jones · 04/26/2023 06:05
*Sanofi Says Waiting Period for Acquisition of Provention Bio Has Expired
Dow Jones · 04/26/2023 06:04
XBI: Uncorrelated Growth Capitalizing On The M&A Tidal Wave In Pharma
Seeking Alpha · 04/21/2023 15:13
Sanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Information
Benzinga · 04/11/2023 18:14
Sanofi Announces Withdrawal, Refiling Of Premerger Notification And Report Form Under HSR Act And Extension Of Tender Offer To Acquire Provention Bio
Benzinga · 04/10/2023 20:19
Strength Seen in Apellis Pharmaceuticals, Inc. (APLS): Can Its 16.3% Jump Turn into More Strength?
NASDAQ · 04/04/2023 08:02
More
Webull provides a variety of real-time PRVB stock news. You can receive the latest news about Provention Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PRVB
Provention Bio, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing the development and commercialization of investigational therapies that intercept and prevent debilitating and life-threatening immune-mediated diseases. The Company’s pipeline includes TZIELD (teplizumab-mzwv), PRV-3279, Ordesekimab and PRV-101. TZIELD (teplizumab-mzwv) is a CD3-directed antibody indicated to delay the onset of stage three T1D in adults and pediatric patients aged eight years and older with stage two T1D. It is also developing TZIELD for use in stage three newly diagnosed T1D patients. PRV-3279 is a humanized bispecific scaffold molecule targeting the B-cell surface proteins for the treatment of SLE and for the prevention of immunogenicity of biotherapeutics. Ordesekimab is a human anti-interleukin 15 (IL-15) monoclonal antibody for the treatment of gluten-free diet non-responsive celiac disease. PRV-101 is a CVB vaccine to prevent acute CVB infections.